Inflammation
Please install or upgrade your Adobe Flash Player to see a video on this topic.
Rheumatoid arthritis is one of the most common autoimmune diseases, affecting more than 21 million people worldwide. In 30–40% of cases conventional drugs are ineffective or poorly tolerated. Now, biopharmaceuticals are paving the way for a new treatment that can impede progression of the disease and prevent joint damage and pain.
Roche goes to the root of the disease
Our researchers are looking to deepen their understanding of the immune system and pinpoint the causes and course of arthritis. Their discoveries have already resulted in new drugs offering real patient benefits. Biopharmaceuticals such as MabThera / Rituxan in rheumatoid arthritis selectively intervene in the molecular course of the disease without weakening the immune system as a whole. This new mechanism of action alleviates pain and holds the disease in check.
The earlier the diagnosis, the better
Currently doctors rely on a constellation of signs and symptoms to make a firm diagnosis of rheumatoid arthritis. By that time many patients are already disabled by their damaged joints. Our goal is earlier detection using a reliable disease indicator in the form of a biomarker incorporated in a diagnostic test. Only then will doctors be able to intervene early enough to prevent joint damage and disability.